RCKT Rocket Corp: Bozor kapitallashuvining balans qiymatiga nisbati

Rocket Pharma (RCKT) kompaniyasining rasmiy ramzlari

Rocket Pharmaceuticals (RCKT) kompaniyasining kunlik narxlar grafigi kompaniyaning faoliyatini aks ettiradi, bunda muvaffaqiyat kamyob kasalliklar terapiyasining samaradorligi va ishlab chiqarishning kengayishiga bog'liq. Joriy ko'rsatkich 0.73 ni tashkil etadi, daromadning yo'qligi esa moliyaviy istiqbollarni tartibga soluvchi organlarning qarorlariga bog'liq qiladi. Daromadli aktivlarning yetishmasligi sababli, biznes barqaror naqd pul oqimi bo'lmagan holda rejalashtirilgan R&D xarajatlari bilan tavsiflanadi.

Rocket Corp (RCKT): Kapitallashuvning balans qiymatiga nisbati 04.07.2022dan 28.10.2026gacha

Rocket Pharma (RCKT) moliyaviy va bozor koʻrsatkichlari kesimi

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Rocket Pharmaceuticals|RCKT - Tahlilchilarning prognoz narxlari
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Rocket Pharmaceuticals Inc|RCKT - Biznes qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Rocket Pharmaceuticals|RCKT - Buxgalteriya kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati rocketpharma.com|RCKT - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Rocket Pharmaceuticals|RCKT - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati Rocket Pharmaceuticals Inc|RCKT - Kompaniyaning umumiy yig'indi qarzi|Balans kapitallashuviga qarzlar Rocket Pharmaceuticals Inc
Kompaniyaning dastlabki tahlili:Rocket Pharmaceuticals, RCKT
Rocket Pharmaceuticals Inc original mahsuloti

Fundamental aktivlarni skrining qilish kompaniyaning o'zining sof aktivlar qiymatidan yuqori bo'lgan bozor qiymatini yaratish qobiliyatini baholashni talab qiladi. Bozor kapitalizatsiyasining buxgalteriya qiymatiga nisbatdagi joriy koeffitsientini tahlil qilish orqali investor o'sish premiyasini aniqlaydi, bu esa Rocket Pharmaceuticals (RCKT) holatida, gen terapiyasini FDA tasdiqlashining qat'iy bosqichlari orqali tijoratlashtirishga yo'naltirishdagi rahbariyatning favqulodda kompetentsiyasi bilan asoslanadi.

Toʻgʻridan-toʻgʻri raqobatchilar

TEM - Kapitallashuvning sof aktivlarga nisbati|qiagen.com (QGEN) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati Ionis (IONS)|Kapitallashuvning balans qiymatiga nisbati RGEN|Bozor qiymatining balans qiymatiga nisbati Avidity RNA|Kapitallashuvning balans qiymatiga nisbati CRISPR (CRSP)|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|ultragenyx.com - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Beam Therapeutics (BEAM)|SRPT: Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati TWST|10x (TXG) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati NTLA|Kapitallashuvning sof aktivlarga nisbati STOK|Bozor qiymatining balans qiymatiga nisbati BLFS|Bozor kapitallashuvining balans qiymatiga nisbati Wave Life Sciences Ltd (WVE)|MAZE: Bozor kapitallashuvining balans qiymatiga nisbati|SION - Bozor qiymatining balans qiymatiga koeffitsiyenti|Kapitallashuvning sof aktivlarga nisbati Prime Medicine, Inc. PRME|tayshagtx.com (TSHA) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Kapitallashuvning sof aktivlarga nisbati uniQure QURE|MGTX (MeiraGTx Holdings) - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Regenxbio RGNX|Sof aktivlarga nisbatan bozor kapitallashuvi Solid Corp|Ocugen, Inc. (OCGN) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati pacb.com (PACB)|Bozor kapitallashuvining balans qiymatiga nisbati BNTC (Benitec Biopharma)|Design Therapeutics Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati 4D Molecular Therapeutics Inc (FDMT)|LXEO: Balans qiymatiga nisbatan bozor qiymati|KRRO (korrobio.com) - Bozor qiymatining balans qiymatiga nisbati|editasmedicine.com (EDIT) - Kapitallashuvning sof aktivlarga nisbati|SLN (Silence Therapeutics plc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati ProQR Therapeutics NV|Bozor kapitallashuvining balans qiymatiga nisbati CDXS (Codexis, Inc.)|Kapitallashuvning sof aktivlarga nisbati Sangamo BioSciences (SGMO)|NAUT: Bozor kapitallashuvining balans qiymatiga nisbati|MGX - Bozor qiymatining balans qiymatiga koeffitsiyenti|Precision BioSciences - Kapitallashuvning sof aktivlarga nisbati|Generation Bio Co. (GBIO) - Bozor kapitallashuvining balans qiymatiga nisbati|BOLD - Kapitallashuvning sof aktivlarga nisbati|Exicure (XCUR) - Bozor kapitallashuvining balans qiymatiga multiplikatori|IMNN: Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi RXi Pharmaceuticals|Bozor kapitallashuvining balans qiymatiga nisbati MBIO (Mustang Bio, Inc.)|Kapitallashuvning sof aktivlarga nisbati transcodetherapeutics.com (RNAZ)|Bozor kapitallashuvining balans qiymatiga nisbati BNGO (Bionano Genomics)|Applied DNA Corp - Bozor kapitallashuvining balans qiymatiga nisbati|BLUE - Bozor qiymatining balans qiymatiga nisbati|IPA: Bozor qiymatining balans qiymatiga nisbati|Omega Therapeutics, Inc. - Bozor qiymatining balans qiymatiga nisbati|OMIC (Singular Genomics Systems, Inc.) - Balans qiymatiga nisbatan bozor kapitallashuvi|RGLS - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati Syros Pharmaceuticals, Inc|Bozor kapitallashuvining balans qiymatiga nisbati TBIO (Telesis Bio, Inc.)|Kapitallashuvning sof aktivlarga nisbati TCON (traconpharma.com)|Bozor qiymatining balans qiymatiga nisbati UBX (Unity Biotechnology, Inc.)